ArticleThe Lancet. Oncology2016
Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study.
Article in The Lancet. Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- [S3 guideline breast cancer: update on early detection, and mammography screening].Der Radiologe · 2019Guideline
- Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.Health technology assessment (Winchester, England) · 2020Trial
- Survival Benefits and Less Intensive Treatment for Women with Early-Stage Breast Cancer Diagnosed While Participating in Population-Based Screening.Annals of surgical oncology · 2025Article
- The natural history of ductal carcinoma in situ: development, validation, and estimated outcomes of the SimDCIS model.Breast cancer research and treatment · 2025Article
- Serum metabolite and metal ions profiles for breast cancer screening.Scientific reports · 2024Article
- Radiology for Ductal Carcinoma In Situ of the Breast: Updates on Invasive Cancer Progression and Active Monitoring.Korean journal of radiology · 2024Review
- Ultrasound deep learning radiomics and clinical machine learning models to predict low nuclear grade, ER, PR, and HER2 receptor status in pure ductal carcinomaGland surgery · 2024Article
- Impact of Breast Cancer Screening on 10-Year Net Survival in Canadian Women Age 40-49 Years.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Deep learning denoising of digital breast tomosynthesis: Observer performance study of the effect on detection of microcalcifications in breast phantom images.Medical physics · 2023Article
- Article
- Clinical value of contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: a population-based cohort study-commentary.European radiology · 2023Article
- Cumulative 6-Year Risk of Screen-Detected Ductal Carcinoma In Situ by Screening Frequency.JAMA network open · 2023Article
- Article
- Lidocaine promotes apoptosis in breast cancer cells by affecting VDAC1 expression.BMC anesthesiology · 2022Article
- Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study.Cell death & disease · 2022Article
- Effects of Luteolin on Human Breast Cancer Using Gene Expression Array: Inferring Novel Genes.Current issues in molecular biology · 2022Article
- Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study.Breast (Edinburgh, Scotland) · 2022Article
- Which type of cancer is detected in breast screening programs? Review of the literature with focus on the most frequent histological features.Pathologica · 2021Review
- An analysis of screen-detected invasive cancers by grade in the English breast cancer screening programme: are we failing to detect sufficient small grade 3 cancers?European radiology · 2021Observational
- Clinicopathological Characteristics of Breast Ductal Carcinoma In Situ: An Analysis of Chinese Population of 617 Patients.Journal of oncology · 2021Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
18 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundThe value of screen detection and treatment of ductal carcinoma in situ (DCIS) is a matter of controversy. At present, the extent to which the diagnosis and treatment of DCIS could prevent the occurrence of invasive breast cancer in the future is not clear. We sought to estimate the association between detection of DCIS at screening and invasive interval cancers subsequent to the relevant screen.
methodsWe obtained aggregate data for screen-detected cancers from 84 local screening units within 11 regional Quality Assurance Reference Centres in England, Wales, and Northern Ireland from the National Health Service Breast Screening Programme. Data for DCIS diagnoses were obtained for women aged 50-64 years who were invited to and attended mammographic breast screening from April 1, 2003, to March 31, 2007 (4 screening years). Patient-level data for interval cancer arising in the 36 months after each of these were analysed by Poisson regression with invasive interval cancer screen detection rate as the outcome variable; DCIS detection frequencies were fitted first as a continuous and then as a categorical variable. We repeated this analysis after adjustment with both small size and high-grade invasive screen-detected cancers.
findingsWe analysed data for 5,243,658 women and on interval cancers occurring in the 36 months after the relevant screen. The average frequency of DCIS detected at screening was 1·60 per 1000 women screened (median 1·50 [unit range 0·54-3·56] [corrected to] per 1000 women). There was a significant negative association of screen-detected DCIS cases with the rate of invasive interval cancers (Poisson regression coefficient -0·084 [95% CI -0·13 to -0·03]; p=0·002). 90% of units had a DCIS detection frequency within the range of 1·00 to 2·22 per 1000 women; in these units, for every three screen-detected cases of DCIS, there was one fewer invasive interval cancer in the next 3 years. This association remained after adjustment for numbers of small screen-detected invasive cancers and for numbers of grade 3 invasive screen-detected cancers.
interpretationThe association between screen-detected DCIS and subsequent invasive interval cancers suggests that detection and treatment of DCIS is worthwhile in prevention of future invasive disease.
fundingUK Department of Health Policy Research Programme and NHS Cancer Screening Programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.